Clinical Trials Directory

Trials / Completed

CompletedNCT00096096

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation. PURPOSE: This phase II trial is studying how well giving tacrolimus together with mycophenolate mofetil works in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation for advanced hematologic cancer.

Detailed description

OBJECTIVES: Primary * Determine the efficacy of tacrolimus and mycophenolate mofetil in preventing acute graft-vs-host disease in patients with advanced hematologic malignancies undergoing allogeneic peripheral blood stem cell transplantation. Secondary * Determine the safety of this regimen in these patients. OUTLINE: This is a non-randomized study. Patients receive tacrolimus IV continuously or orally twice daily on days -1 to 60 followed by a taper to day 180. Patients also receive mycophenolate mofetil IV over 2 hours or orally twice daily on days 0-60 followed by a taper to day 180. Treatment is discontinued at day 180 in the absence of graft-vs-host disease. Patients are followed for survival. PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGmycophenolate mofetil
DRUGtacrolimus

Timeline

Start date
2004-08-01
Primary completion
2006-05-01
First posted
2004-11-09
Last updated
2010-05-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00096096. Inclusion in this directory is not an endorsement.